Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- BCDAW
- Price
- -
- Stock movement down
- -0.00 (-1.61%)
- Company name
- BioCardia Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- -
- Ent value
- 3.43M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 8.43%
- 1 year return
- -98.95%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2024-12-16
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
BCDAW does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | 8.01 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | - |
| EPS (TTM) | -4.56 |
| FCF per share (TTM) | -3.79 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 428.00K |
| Gross profit (TTM) | 7.00K |
| Operating income (TTM) | -8.58M |
| Net income (TTM) | -8.56M |
| EPS (TTM) | -4.56 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 1.64% |
| Operating margin (TTM) | -2005.14% |
| Profit margin (TTM) | -1999.77% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.42M |
| Net receivables | 10.00K |
| Total current assets | 1.57M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 1.88M |
| Total assets | 2.89M |
| Accounts payable | 1.45M |
| Short/Current long term debt | 1.14M |
| Total current liabilities | 4.07M |
| Total liabilities | 4.85M |
| Shareholder's equity | -1.96M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -7.11M |
| Capital expenditures (TTM) | 3.00K |
| Free cash flow (TTM) | -7.11M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -296.16% |
| Return on Invested Capital | 533.94% |
| Cash Return on Invested Capital | 443.42% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| BCDAW | S&P500 | |
| Current price drop from All-time high | -99.75% | -5.66% |
| Highest price drop | -99.75% | -56.47% |
| Date of highest drop | 2 Aug 2024 | 9 Mar 2009 |
| Avg drop from high | -61.54% | -11.07% |
| Avg time to new high | 51 days | 12 days |
| Max time to new high | 442 days | 1805 days |
COMPANY DETAILS
Marketcap
-
Marketcap category
Small-cap
Description
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
Employees
16
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner